Emergency: 911 Crisis: call or text 988 PA DDAP: 1-800-662-4357 PA 211: 2-1-1
24/7 Placement Advisors — Call (215) 792-4574
Philadelphia — Available 24/7

Inpatient Drug Rehab in Philadelphia | Anchor Point Addiction Center

We connect Philadelphia residents with licensed inpatient treatment programs. Insurance verified free — many PPO plans cover inpatient rehab.

  • Insurance Verified Free
  • Available 24/7
  • PPO Plans Accepted
  • Same-Day Placement

Philadelphia recorded 1,069 unintentional overdose deaths in 2024 — an 18% decline from 2023 and 24% below the record 1,413 deaths in 2022, according to the Philadelphia Department of Public Health. Progress is real, and the crisis isn't over.

Philadelphia Inpatient Drug Rehab — Available 24/7

Anchor Point Addiction Center connects Philadelphia-area residents and families with licensed inpatient addiction treatment. Free insurance verification, 24/7 placement.

🏥

Inpatient Rehab

24/7 medically supervised residential treatment — the highest level of care for fentanyl, heroin, alcohol, and poly-drug dependence.

💊

Medical Detox

Philadelphia's drug supply now includes fentanyl, xylazine, and medetomidine. Safe medical detox is critical — home detox is dangerous.

🧠

Dual Diagnosis

Addiction rarely travels alone. Licensed programs treat co-occurring depression, anxiety, PTSD, and trauma alongside substance use disorder.

📋

Insurance Verification

PA Act 106 requires minimum SUD coverage in group insurance policies. We verify your benefits in minutes — free, confidential, no obligation.

Ready to Talk? Call (215) 792-4574 — Available 24/7.

Free insurance verification in minutes. We tell you what your plan covers in one call. Confidential, no obligation.

(215) 792-4574

Philadelphia's Overdose Crisis — 2024 Data

Sources: Philadelphia Department of Public Health — 2024 overdose report, 2023 substance data, overdose location (2021); CDC MMWR (medetomidine).

1,069
Overdose Deaths
Philadelphia 2024
↓18%
Decline from 2023
Second consecutive drop
80%
Involved Fentanyl
2023 drug-involved deaths
38%
Involved Xylazine
2023 deaths
63%
Involved Cocaine
2023 deaths
69%
Occurred at Home
Fatal ODs, 2021
⚠️ Medetomidine Alert

In the last four months of 2024, medetomidine — a veterinary sedative — was detected in 72% of illegal opioid samples tested in Philadelphia, while xylazine fell to 31% (CDC MMWR). Naloxone doesn't reverse it, and its withdrawal can cause severe high blood pressure and a racing heart. Medical detox is now more important than ever.

Call (215) 792-4574 — Placement Advisors Available 24/7

PA Act 106 requires minimum addiction treatment coverage in group insurance policies. Free, confidential insurance verification in minutes.

(215) 792-4574

What Is Inpatient Drug Rehab?

Inpatient drug rehab — also called residential treatment — is a 24/7 live-in program that provides medical supervision, individual therapy, group counseling, and structured support for people with moderate-to-severe substance use disorder. Unlike outpatient treatment, patients live on site at a licensed program in the referral network for the length of their stay, removing them from the environment and triggers that contribute to continued use. For Philadelphians dealing with fentanyl, xylazine, medetomidine, or poly-drug dependence, inpatient care is typically the safest and most effective starting point.

Why Philadelphia Residents Need Specialized Inpatient Care

Philadelphia's drug supply is unusually complex. Fentanyl was involved in 80% of the city's drug-involved overdose deaths in 2023 (PDPH) — and it's now commonly combined with xylazine ('tranq'), which causes severe skin wounds that standard addiction treatment doesn't address, and medetomidine, a veterinary sedative detected in 72% of illegal opioid samples tested in Philadelphia in the last four months of 2024 (CDC MMWR). This poly-drug reality means that standard detox protocols designed for heroin or alcohol aren't sufficient. Inpatient programs that understand Philadelphia's specific drug landscape — and can manage xylazine wounds, medetomidine withdrawal, and fentanyl dependence simultaneously — provide a level of care that outpatient settings simply can't match.

Does Insurance Cover Inpatient Rehab in Philadelphia?

In most cases, yes. Pennsylvania's Act 106 requires minimum coverage for alcohol and substance use disorder treatment (PA Insurance Department) in group insurance policies. Federal parity law (MHPAEA) keeps most plans from applying stricter copays, deductibles or visit limits to addiction treatment than to medical or surgical care (U.S. Department of Labor). What you pay depends on your plan's deductible and out-of-pocket maximum; a placement advisor can give you real numbers for your policy in one call at (215) 792-4574.

1,069
Philadelphia OD Deaths
2024
↓24%
Below 2022 Peak
Philadelphia, 2024
24/7
Placement Advisors
Call anytime
Act 106
PA Insurance Mandate
SUD coverage required

Frequently Asked Questions About Philadelphia Inpatient Rehab

How long does inpatient drug rehab take in Philadelphia?

It depends on the person. The licensed program's clinical team sets the length of stay after an assessment, based on the substances involved, detox needs, co-occurring conditions and treatment history. For Philadelphia residents dealing with fentanyl and poly-drug dependence — particularly where xylazine or medetomidine is involved — longer stays are often recommended, since these substances can need extended stabilization and wound care. A placement advisor can explain what the programs that fit you typically offer.

Does insurance pay for drug rehab in Philadelphia?

Many commercial plans include residential SUD benefits. Pennsylvania's Act 106 sets minimum coverage for alcohol and substance use disorder treatment in group insurance policies (PA Insurance Department), and federal parity law (MHPAEA) keeps most plans from applying stricter copays, deductibles or visit limits to addiction care than to medical or surgical care (U.S. Department of Labor). What you pay depends on your plan's deductible and out-of-pocket maximum; a placement advisor can give you real numbers for your policy in one call at (215) 792-4574.

What is xylazine and why does it matter for rehab?

Xylazine — known as 'tranq' on the street — is a veterinary sedative mixed into the Philadelphia drug supply. It was involved in 38% of the city's overdose deaths in 2023 (PDPH). Naloxone does not reverse xylazine. It also causes severe, slow-healing skin wounds that require specialized wound care during treatment. Inpatient programs in Philadelphia have adapted protocols to treat xylazine-involved dependence — this is why specialized local placement matters.

What is medetomidine and is it in Philadelphia's drug supply?

Yes. Medetomidine is a veterinary sedative that has largely displaced xylazine in Philadelphia's drug supply: in the last four months of 2024 it was detected in 72% of illegal opioid samples tested, while xylazine fell to 31% (CDC MMWR). Its withdrawal can include severe high blood pressure, a racing heart, tremor and vomiting. Medical detox under clinical supervision is critical for anyone using street drugs in Philadelphia.

How do I get into rehab quickly in Philadelphia?

Call (215) 792-4574 — placement advisors are available 24/7. They will verify your insurance on the call, identify available inpatient programs that match your clinical needs, and help arrange admission as quickly as same day in many cases. You do not need a referral from a doctor. You do not need to have everything figured out. You just need to call.

Call Now